Sanofi Posts Stronger-than-expected Result In Q4, Eyes More Cost Cuts

PARIS (Reuters) - Sanofi said on Friday it aimed to grow earnings per share this year after it posted stronger-than-expected results in the fourth quarter, and the drugmaker hiked its cost cutting target as part of a bid to boost margins.

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30% for 2022 and set itself a goal to improve it to more than 32% three years later.

It stood at 27.1% in 2020.

Sanofi, which is cutting just under 1,700 jobs in Europe, raised a late 2019 goal of generating 2 billion euros ($2.39 billion) in savings by 2022 by 500 million euros.

The company is hosting a virtual investor day later on Friday that will largely focus on upcoming drugs.

Sanofi's earnings per share in the fourth quarter were up 9.8% at constant exchange rates to 1.22 euros.

Total sales rose 4.2% to 9.4 billion euros thanks to another strong revenue increase of its eczema treatment Dupixent and what it described as a "record demand" for its influenza vaccines.

Analysts polled by Refinitiv were expecting quarterly earnings per share of 1.16 euros and sales of 9.6 billion euros.

($1 = 0.8363 euros)

(Reporting by Matthias Blamont; Editing by Sarah White)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor